tiprankstipranks
Ocular Therapeutix Inc (DE:0OT)
NASDAQ:0OT
Germany Market
0OT
Ocular Therapeutix
RESEARCH TOOLSreports

Ocular Therapeutix (0OT) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

0OT Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Ocular
Therapeutix
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0OT Stock 12 Month Forecast

Average Price Target

€22.37
▲(202.32% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is €22.37 with a high forecast of €26.90 and a low forecast of €15.62. The average price target represents a 202.32% change from the last price of €7.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","27":"€27","11.25":"€11.25","16.5":"€16.5","21.75":"€21.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26.904280619999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€26.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.37201829333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€22.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.62184036,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€15.62</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,11.25,16.5,21.75,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.2,8.715713893846154,10.231427787692308,11.747141681538462,13.262855575384616,14.77856946923077,16.29428336307692,17.809997256923076,19.32571115076923,20.841425044615384,22.35713893846154,23.872852832307693,25.388566726153844,{"y":26.904280619999998,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.2,8.36707833025641,9.53415666051282,10.70123499076923,11.86831332102564,13.035391651282051,14.20246998153846,15.369548311794869,16.53662664205128,17.70370497230769,18.8707833025641,20.037861632820512,21.20493996307692,{"y":22.37201829333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.2,7.847833873846154,8.495667747692307,9.143501621538462,9.791335495384615,10.43916936923077,11.087003243076923,11.734837116923078,12.382670990769231,13.030504864615384,13.67833873846154,14.326172612307694,14.974006486153847,{"y":15.62184036,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.235,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.704,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.094,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.292,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€26.90Average Price Target€22.37Lowest Price Target€15.62
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:0OT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€23.43
Buy
216.66%
Upside
Reiterated
08/07/26
Bank of America Securities Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)
Clear Street Analyst forecast on DE:0OT
William Maughan
Clear Street
Clear Street
€24.3
Buy
228.39%
Upside
Reiterated
08/04/26
Clear Street Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)
H.C. Wainwright Analyst forecast on DE:0OT
Yi Chen
H.C. Wainwright
H.C. Wainwright
€21.7
Buy
193.20%
Upside
Reiterated
08/04/26
Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Keros Therapeutics (KROS)
TD Cowen Analyst forecast on DE:0OT
Tara Bancroft
TD Cowen
TD Cowen
€17.36
Buy
134.56%
Upside
Reiterated
08/03/26
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
Needham Analyst forecast on DE:0OT
Serge Belanger
Needham
Needham
€15.62
Buy
111.11%
Upside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (NASDAQ: OCUL) and Addus Homecare (NASDAQ: ADUS)
RBC Capital Analyst forecast on DE:0OT
Lisa Walter
RBC Capital
RBC Capital
€26.04
Buy
251.84%
Upside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Ocular Therapeutix (NASDAQ: OCUL) and Arcus Biosciences (NYSE: RCUS)
William Blair Analyst forecast on DE:0OT
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
08/03/26
Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Twist Bioscience (TWST)
Chardan Capital Analyst forecast on DE:0OT
Daniil Gataulin
Chardan Capital
Chardan Capital
€18.23→€19.96
Buy
169.75%
Upside
Reiterated
06/25/26
Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)
Piper Sandler Analyst forecast on DE:0OT
Biren Amin
Piper Sandler
Piper Sandler
€26.9
Buy
263.57%
Upside
Reiterated
06/18/26
Piper Sandler Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)
Robert W. Baird Analyst forecast on DE:0OT
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
€20.83→€26.04
Buy
251.84%
Upside
Reiterated
06/18/26
Ocular Therapeutix price target raised to $30 from $24 at BairdOcular Therapeutix price target raised to $30 from $24 at Baird
Citizens JMP Analyst forecast on DE:0OT
Jonathan Wolleben
Citizens JMP
Citizens JMP
―
Buy
―
Reiterated
02/17/26
Ocular Therapeutix selloff brings attractive entry point, says CitizensOcular Therapeutix selloff brings attractive entry point, says Citizens
Jefferies Analyst forecast on DE:0OT
Clara Dong
Jefferies
Jefferies
€24.3
Buy
228.39%
Upside
Reiterated
02/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:0OT
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€23.43
Buy
216.66%
Upside
Reiterated
08/07/26
Bank of America Securities Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)
Clear Street Analyst forecast on DE:0OT
William Maughan
Clear Street
Clear Street
€24.3
Buy
228.39%
Upside
Reiterated
08/04/26
Clear Street Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)
H.C. Wainwright Analyst forecast on DE:0OT
Yi Chen
H.C. Wainwright
H.C. Wainwright
€21.7
Buy
193.20%
Upside
Reiterated
08/04/26
Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Keros Therapeutics (KROS)
TD Cowen Analyst forecast on DE:0OT
Tara Bancroft
TD Cowen
TD Cowen
€17.36
Buy
134.56%
Upside
Reiterated
08/03/26
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
Needham Analyst forecast on DE:0OT
Serge Belanger
Needham
Needham
€15.62
Buy
111.11%
Upside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (NASDAQ: OCUL) and Addus Homecare (NASDAQ: ADUS)
RBC Capital Analyst forecast on DE:0OT
Lisa Walter
RBC Capital
RBC Capital
€26.04
Buy
251.84%
Upside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Ocular Therapeutix (NASDAQ: OCUL) and Arcus Biosciences (NYSE: RCUS)
William Blair Analyst forecast on DE:0OT
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
08/03/26
Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Twist Bioscience (TWST)
Chardan Capital Analyst forecast on DE:0OT
Daniil Gataulin
Chardan Capital
Chardan Capital
€18.23→€19.96
Buy
169.75%
Upside
Reiterated
06/25/26
Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)
Piper Sandler Analyst forecast on DE:0OT
Biren Amin
Piper Sandler
Piper Sandler
€26.9
Buy
263.57%
Upside
Reiterated
06/18/26
Piper Sandler Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)
Robert W. Baird Analyst forecast on DE:0OT
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
€20.83→€26.04
Buy
251.84%
Upside
Reiterated
06/18/26
Ocular Therapeutix price target raised to $30 from $24 at BairdOcular Therapeutix price target raised to $30 from $24 at Baird
Citizens JMP Analyst forecast on DE:0OT
Jonathan Wolleben
Citizens JMP
Citizens JMP
―
Buy
―
Reiterated
02/17/26
Ocular Therapeutix selloff brings attractive entry point, says CitizensOcular Therapeutix selloff brings attractive entry point, says Citizens
Jefferies Analyst forecast on DE:0OT
Clara Dong
Jefferies
Jefferies
€24.3
Buy
228.39%
Upside
Reiterated
02/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocular Therapeutix

3 Months
Jonathan WollebenCitizens JMP
Success Rate
18/28 ratings generated profit
64%
Average Return
+15.46%
Copying Jonathan Wolleben's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +15.46% per trade.
1 Year
Jonathan WollebenCitizens JMP
Success Rate
19/28 ratings generated profit
68%
Average Return
+43.91%
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 67.86% of your transactions generating a profit, with an average return of +43.91% per trade.
2 Years
Jonathan WollebenCitizens JMP
Success Rate
25/28 ratings generated profit
89%
Average Return
+96.88%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 89.29% of your transactions generating a profit, with an average return of +96.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0OT Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
24
14
16
14
15
Buy
6
4
4
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
18
20
16
17
In the current month, 0OT has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0OT average Analyst price target in the past 3 months is 22.37.
Each month's total comprises the sum of three months' worth of ratings.

0OT Financial Forecast

0OT Earnings Forecast

Next quarter’s earnings estimate for 0OT is -€0.32 with a range of -€0.33 to -€0.28. The previous quarter’s EPS was -€0.30. 0OT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.38% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0OT is -€0.32 with a range of -€0.33 to -€0.28. The previous quarter’s EPS was -€0.30. 0OT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.38% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.

0OT Sales Forecast

Next quarter’s sales forecast for 0OT is €12.39M with a range of €11.63M to €13.89M. The previous quarter’s sales results were €11.69M. 0OT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 30.71% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.
Next quarter’s sales forecast for 0OT is €12.39M with a range of €11.63M to €13.89M. The previous quarter’s sales results were €11.69M. 0OT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 30.71% of the time in the same period. In the last calendar year 0OT has Performed in-line its overall industry.

0OT Stock Forecast FAQ

What is DE:0OT’s average 12-month price target, according to analysts?
Based on analyst ratings, Ocular Therapeutix Inc’s 12-month average price target is 22.37.
    What is DE:0OT’s upside potential, based on the analysts’ average price target?
    Ocular Therapeutix Inc has 202.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Ocular Therapeutix Inc a Buy, Sell or Hold?
          Ocular Therapeutix Inc has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ocular Therapeutix Inc’s share price target?
            The average share price target for Ocular Therapeutix Inc is 22.37. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €26.90 ,and the lowest forecast is €15.62. The average share price target represents 202.32% Increase from the current price of €7.4.
              What do analysts say about Ocular Therapeutix Inc?
              Ocular Therapeutix Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Ocular Therapeutix Inc?
                To buy shares of DE:0OT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.